What question did this study set out to answer?

This research aims to explore how the ESM1-ANGPTL4-FASN-trioleate axis contributes to cancer progression and treatment resistance.

March 24, 2026Open Access

View Full Paper

ESM1 drives cancer angiogenesis and bevacizumab resistance via trioleate synthesis

XCXun ChenHebei Medical University JWJian WanCentral South University ZJZhengwu JiangCentral South University

Key Points

This research aims to explore how the ESM1-ANGPTL4-FASN-trioleate axis contributes to cancer progression and treatment resistance.
Analyzed the role of ESM1 in metabolic reprogramming and endothelial activation.
Investigated the ESM1-ANGPTL4-FASN-trioleate axis in the context of cancer angiogenesis.
Proposed combination therapies to target this metabolic pathway.
ESM1 promotes angiogenesis and resistance to bevacizumab in cancer.
Trioleate synthesis is linked to the metabolic alterations observed in endothelial cells.
Targeting the ESM1 axis could enhance therapeutic responses in hepatocellular carcinoma.

Abstract

The ESM1-ANGPTL4-FASN-trioleate axis orchestrates metabolic reprogramming and endothelial activation, representing a promising therapeutic target. Future studies should explore combination therapies targeting this axis and overcoming bevacizumab resistance in HCC.

AI से पूछें

Bookmark

View Full Paper

AI से पूछें

Bookmark

View Full Paper

ESM1 drives cancer angiogenesis and bevacizumab resistance via trioleate synthesis

Key Points

Abstract

Cite This Study